File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Elevation of Plasma TGF-β1 During Radiation Therapy Predicts Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer: A Combined Analysis From Beijing and Michigan

TitleElevation of Plasma TGF-β1 During Radiation Therapy Predicts Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer: A Combined Analysis From Beijing and Michigan
Authors
KeywordsMean lung dose
Radiation-induced lung toxicity
Non-small-cell lung cancer
Transforming growth factor β1
Issue Date2009
Citation
International Journal of Radiation Oncology Biology Physics, 2009, v. 74, n. 5, p. 1385-1390 How to Cite?
AbstractPurpose: To test whether radiation-induced elevations of transforming growth factor-β1 (TGF-β1) during radiation therapy (RT) correlate with radiation-induced lung toxicity (RILT) in patients with non-small-cell lung cancer (NSCLC) and to evaluate the ability of mean lung dose (MLD) to improve the predictive power. Methods and Materials: Eligible patients included those with Stage I-III NSCLC treated with RT with or without chemotherapy. Platelet-poor plasma was obtained pre-RT and at 4-5 weeks (40-50 Gy) during RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint was ≥ Grade 2 RILT. Mann-Whitney U test, logistic regression, and chi-square were used for statistical analysis. Results: A total of 165 patients were enrolled in this study. The median radiation dose was 60 Gy, and the median MLD was 15.3 Gy. Twenty-nine patients (17.6%) experienced RILT. The incidence of RILT was 46.2% in patients with a TGF-β1 ratio > 1 vs. 7.9% in patients with a TGF-β1 ratio ≤ 1 (p < 0.001), and it was 42.9% if MLD > 20 Gy vs. 17.4% if MLD ≤ 20 Gy (p = 0.024). The incidence was 4.3% in patients with a TGF-β1 ratio ≤ 1 and MLD ≤ 20 Gy, 47.4% in those with a TGF-β1 ratio >1 or MLD > 20 Gy, and 66.7% in those with a TGF-β1 ratio >1 and MLD > 20 Gy (p < 0.001). Conclusions: Radiation-induced elevation of plasma TGF-β1 level during RT is predictive of RILT. The combination of TGF- β1 and MLD may help stratify the patients for their risk of RILT. © 2009 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/266898
ISSN
2020 Impact Factor: 7.038
2020 SCImago Journal Rankings: 2.117
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhao, Lujun-
dc.contributor.authorWang, Luhua-
dc.contributor.authorJi, Wei-
dc.contributor.authorWang, Xiaozhen-
dc.contributor.authorZhu, Xiangzhi-
dc.contributor.authorHayman, James A.-
dc.contributor.authorKalemkerian, Gregory P.-
dc.contributor.authorYang, Weizhi-
dc.contributor.authorBrenner, Dean-
dc.contributor.authorLawrence, Theodore S.-
dc.contributor.authorKong, Feng Ming-
dc.date.accessioned2019-01-31T07:19:55Z-
dc.date.available2019-01-31T07:19:55Z-
dc.date.issued2009-
dc.identifier.citationInternational Journal of Radiation Oncology Biology Physics, 2009, v. 74, n. 5, p. 1385-1390-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://hdl.handle.net/10722/266898-
dc.description.abstractPurpose: To test whether radiation-induced elevations of transforming growth factor-β1 (TGF-β1) during radiation therapy (RT) correlate with radiation-induced lung toxicity (RILT) in patients with non-small-cell lung cancer (NSCLC) and to evaluate the ability of mean lung dose (MLD) to improve the predictive power. Methods and Materials: Eligible patients included those with Stage I-III NSCLC treated with RT with or without chemotherapy. Platelet-poor plasma was obtained pre-RT and at 4-5 weeks (40-50 Gy) during RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint was ≥ Grade 2 RILT. Mann-Whitney U test, logistic regression, and chi-square were used for statistical analysis. Results: A total of 165 patients were enrolled in this study. The median radiation dose was 60 Gy, and the median MLD was 15.3 Gy. Twenty-nine patients (17.6%) experienced RILT. The incidence of RILT was 46.2% in patients with a TGF-β1 ratio > 1 vs. 7.9% in patients with a TGF-β1 ratio ≤ 1 (p < 0.001), and it was 42.9% if MLD > 20 Gy vs. 17.4% if MLD ≤ 20 Gy (p = 0.024). The incidence was 4.3% in patients with a TGF-β1 ratio ≤ 1 and MLD ≤ 20 Gy, 47.4% in those with a TGF-β1 ratio >1 or MLD > 20 Gy, and 66.7% in those with a TGF-β1 ratio >1 and MLD > 20 Gy (p < 0.001). Conclusions: Radiation-induced elevation of plasma TGF-β1 level during RT is predictive of RILT. The combination of TGF- β1 and MLD may help stratify the patients for their risk of RILT. © 2009 Elsevier Inc. All rights reserved.-
dc.languageeng-
dc.relation.ispartofInternational Journal of Radiation Oncology Biology Physics-
dc.subjectMean lung dose-
dc.subjectRadiation-induced lung toxicity-
dc.subjectNon-small-cell lung cancer-
dc.subjectTransforming growth factor β1-
dc.titleElevation of Plasma TGF-β1 During Radiation Therapy Predicts Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer: A Combined Analysis From Beijing and Michigan-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ijrobp.2008.10.065-
dc.identifier.pmid19231104-
dc.identifier.scopuseid_2-s2.0-67651083729-
dc.identifier.volume74-
dc.identifier.issue5-
dc.identifier.spage1385-
dc.identifier.epage1390-
dc.identifier.isiWOS:000268346100013-
dc.identifier.issnl0360-3016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats